Today, based in Jasper, Ind., I'm a maker of office and hospitality furnishings, such as desks, cubicle systems, dressers, fabric wall panels, chairs and vanities. With a market value recently near $65 billion, Biogen (Nasdaq: BIIB) is a biotech giant. Biogen's top seller is its multiple sclerosis drug Tecfidera, sales of which have been growing briskly, but more slowly than many expected. [...] Biogen's pipeline features MS drug daclizumab, which could generate billions of dollars for Biogen if approved, and an Alzheimer's drug, aducanumab. Seemingly promising treatments for Alzheimer's disease have flopped in the past, but if one earns approval, it will likely prove quite profitable. Biogen is also aiming to profit via label expansions for MS drugs Tysabri and Tecfidera and blood cancer drug Gazyva - getting the already approved drugs sanctioned for new treatments.